$1.4B Zyprexa Deal Could Spark More Qui Tam Suits

By Erin Marie Daly

Law360, New York (January 15, 2009, 12:00 AM ET) -- Eli Lilly & Co.'s record-breaking $1.4 billion deal to settle charges that it illegally marketed its anti-psychotic treatment Zyprexa for off-label use could stimulate, one observer says, a wave of false as well as legitimate whistleblower complaints.

The Indiana-based pharmaceutical giant's agreement with the U.S. Attorney's Office for the Eastern District of Pennsylvania and 30 states, announced Thursday, is believed to be the largest-ever health care fraud settlement and resolves four qui tam cases that were consolidated in the U.S. District Court for the Eastern District...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles